Incorporating MDMA as an Adjunct in Emotionally Focused Couples Therapy With Clients Impacted by Trauma or PTSD

Abstract

This article explores incorporating 3,4-methylenedioxymethamphetamine (MDMA) as an adjunct in emotionally focused couples therapy (EFT) with clients in which at least one participant has endured a traumatic experience and reports symptoms of post-traumatic stress disorder (PTSD). Despite classification as a Schedule I drug on the Controlled Substances Act (CSA), in 2017 the U.S. Food and Drug Administration designated MDMA as a “breakthrough therapy” in the treatment of PTSD and approved plans for a Phase 3 clinical trial sponsored by the Multidisciplinary Association for Psychedelic Studies. This article aims to integrate previous and current research involving the therapeutic use of MDMA-assisted psychotherapy into the treatment of PTSD with the systemic, evidence-based approach of EFT.